JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266660

Human WDR83OS (C19orf56) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

WDR83OS KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and 8 bp deletion in exon 1.

View Alternative Names

C19orf56, CS056_HUMAN, Chromosome 19 open reading frame 56, Hypothetical protein LOC51398, PTD008, UPF0139 membrane protein C19orf56

2 Images
Sanger Sequencing - Human WDR83OS (C19orf56) knockout HEK-293T cell line (AB266660)
  • Sanger seq

Unknown

Sanger Sequencing - Human WDR83OS (C19orf56) knockout HEK-293T cell line (AB266660)

Allele-2 : 7 bp deletion in exon 1.

Sanger Sequencing - Human WDR83OS (C19orf56) knockout HEK-293T cell line (AB266660)
  • Sanger seq

Unknown

Sanger Sequencing - Human WDR83OS (C19orf56) knockout HEK-293T cell line (AB266660)

Allele-1 : 8 bp deletion in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and 8 bp deletion in exon 1

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266660-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266660 Human WDR83OS (C19orf56) knockout HEK-293T cell line", "number":"AB266660-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266660-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266660 Human WDR83OS (C19orf56) knockout HEK-293T cell line", "number":"AB266660-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
WDR83OS
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C19orf56 also known as MONA or INIP functions as an important player in DNA repair processes specifically homologous recombination. It has a molecular weight of approximately 26 kDa. This protein shows expression across various tissues but appears more prominently in the testis and thymus. As part of DNA repair machinery C19orf56 participates in maintaining genome stability by facilitating accurate DNA exchange during cell division.
Biological function summary

The maintenance of genome integrity involves the activity of C19orf56. C19orf56 operates within the DNA damage response and associates with other components to form repair complexes. It is necessary for effective repair of double-strand breaks which protects cells from accumulating mutations. The protein acts in coordination with diverse repair enzymes and structural proteins to detect and correct DNA damage ensuring genomic stasis.

Pathways

C19orf56 serves an essential role in the homologous recombination repair pathway. It interacts closely with proteins like RAD51 an important partner within this pathway. The protein also contributes to the DNA damage signaling pathway where it may interact with p53 an important regulator of the cell cycle and apoptosis. This shows the protein's function in important cellular mechanisms governing cell division and stability.

C19orf56 shows connections to conditions like cancer and Fanconi anemia. Alterations in its function can lead to genomic instability increasing cancer susceptibility. Its interaction with BRCA1 indicates a potential impact on breast cancer pathology where ineffective repair pathways may facilitate oncogenic transformations. Also defects in C19orf56 have associations with impaired bone marrow function seen in Fanconi anemia linking the protein to hematopoietic disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com